SAN DIEGO--(BUSINESS WIRE)--Jan. 21, 2009--Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, today announced that it has received permission to investigate alternatives to its announced merger with the Elitech Group. Nanogen requested and Elitech agreed to waive the restrictions in the Share Exchange Agreement related to Nanogen's right to investigate alternatives because Nanogen and Elitech believe it is unlikely that closing conditions to the merger contemplated by the Share Exchange Agreement will be met by March 31, 2009.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.